# of Displayed Technologies: 1 / 1

Applied Category Filter (Click To Remove): Huntington's Disease


Reduction of Toxic Small Huntington Protein by Targeting Both Exon 1 mRNA and Mutant Huntington Protein Cleavage Pathways
TS-000497 — Huntington’s Disease (HD) is a late onset progressive neurodegenerative disorder that results in death in 10-15 years after the first sign of symptoms. Existing oligonucleotides (AONs) based therapies are imperfect as they knockdown wildtype protein, require consistent re-injections, and use potentially harmful molecules. Gene therapy experts at Nationwide Children’s have devised a gene therapy approach that uses a specific snRNA to stably and safely reduce the highly pathogenic protein HTT. By enabling a continuous expression of the therapeutic RNA in the nervous system (and other targets), this technology may delay the age of onset, slow symptom progression, and reduce symptom severity of HD. Hence, it has the potential to become the optimal therapeutic strategy for the treatment of HD.
  • College:
  • Inventors: Wein, Nicolas; Lesman, Daniel; Meyer, Kathrin
  • Licensing Officer: Eidahl, Jocelyn

Loading icon